The BIIB080 Phase 1b clinical study is the first to show a reduction of this magnitude in tau PET across…
WARREN, N.J., March 29, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients’…
ROSELAND, N.J., March 29, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments,…
PMN310 demonstrated greater selectivity for target toxic oligomers over monomers compared to other amyloid-beta-directed antibodies. Greater selectivity of PMN310 for…
SUNNYVALE, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the…
Company Progresses Preclinical Next-Generation oral KIT Inhibitor for Mast Cell-Mediated Inflammatory DiseasesSAN FRANCISCO, March 29, 2023 (GLOBE NEWSWIRE) -- Third…
– Phase 2b clinical trial for AB-2004 in autism irritability ongoing and enrollment anticipated to be complete by end of…
Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1; initiation of clinical…
Uppsala, Sweden, March 29, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced that the regional proteomic…
UPPSALA, Sweden, March 29, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced that the regional proteomic…